New Options in Myelodysplastic Syndromes From ASCO 2022

Amy DeZern, MD


June 28, 2022

Amy DeZern, a leading oncologist from Johns Hopkins University School of Medicine, examines promising new data in myelodysplastic syndromes (MDS) from the 2022 American Society of Clinical Oncology Annual Meeting.

First, she discusses the MEDALIST trial of luspatercept in patients with lower-risk MDS, which showed durable responses. More than half of patients were still on the drug after a year of treatment.

In higher-risk MDS, Dr DeZern discusses the 5F9005 phase 1b study, in which the CD47-blocking monoclonal antibody magrolimab plus azacitidine achieved promising efficacy in untreated patients. Anemia, a potentially concerning adverse effect, was manageable.

In another study of higher-risk patients, the anti–PD-1 agent sintilimab plus decitabine was investigated as first-line treatment and was reported to have anti-tumor activity and a tolerable safety profile.

Targeted therapy in IDH1-mutant relapse/refractory MDS is the topic of the next abstract. Dr DeZern looks at data indicating that ivosidenib offered durable remissions and transfusion independence in a phase 1 trial.

Last, Dr DeZern talks about two trials in progress — one investigating an oral inhibitor of BCL2, the second comparing tamibarotene or placebo alongside azacitidine in newly diagnosed RARA-positive patients.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.